Mortality rate in neonates infected with extended-spectrum β lactamase-producing Klebsiella species and selective empirical use of meropenem

Annals of Tropical Paediatrics

Volumn 29, Issue 2, 2009, Pages 101-110

  Velaphi, S ^a   Wadula, J ^b   Nakwa, F ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFOTAXIME; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; MEROPENEM; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN; ANTIINFECTIVE AGENT; BETA LACTAMASE; DRUG DERIVATIVE; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN TAZOBACTAM COMBINATION PRODUCT; PIPERACILLIN-TAZOBACTAM COMBINATION PRODUCT; THIENAMYCIN DERIVATIVE;

AGE DISTRIBUTION; ARTICLE; ASSISTED VENTILATION; BACTERIUM CULTURE; CARDIOPULMONARY INSUFFICIENCY; CONTROLLED STUDY; DRUG USE; HUMAN; INFANT; KLEBSIELLA; KLEBSIELLA INFECTION; MAJOR CLINICAL STUDY; NEWBORN MORTALITY; RISK FACTOR; VAGINAL DELIVERY; ANTIBIOTIC RESISTANCE; BIOSYNTHESIS; COHORT ANALYSIS; DRUG ADMINISTRATION; ENZYMOLOGY; FEMALE; MALE; MICROBIOLOGY; MORTALITY; NEWBORN; PREGNANCY; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SURVIVAL;

AMIKACIN; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT, NEWBORN; KLEBSIELLA; KLEBSIELLA INFECTIONS; MALE; PENICILLANIC ACID; PIPERACILLIN; PREGNANCY; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; THIENAMYCINS;

EID: 67650497793     PISSN: 02724936     EISSN: 14653281     Source Type: Journal    
DOI: 10.1179/146532809X440716     Document Type: Article

References (44)

1. Knothe H, Shah P, Kremery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983; 11:315-317 (Pubitemid 14213754)
2. Burwen DR, Banerjee SN, Gaynes RP. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. National Nosocomial Infections Surveillance System. J Infect Dis 1994; 170:1622-1625
3. Itokazu GS, Quinn JP, Bell-Dixon C, Kahan FM, Weinstein RA. Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program. Clin Infect Dis 1996; 23:779-784
4. Musoke RN, Revathi G. Emergence of multidrug-resistant gram-negative organisms in a neonatal unit and the therapeutic implications. J Trop Pediatr 2000; 46:86-91. (Pubitemid 30232543)
5. Gregersen N, Van Nierop W, Von Gottenberg A, Duse A, Davies V, Cooper P. Klebsiella pneumoniae with extended spectrum beta-lactamase activity associated with necrotizing enterocolitis outbreak. Pediatr Infect Dis J 1999; 18:963-967
6. Coovadia YM, Johnson AP, Bhana RH, Hutchinson GR, George RC, Hafferjee IE. Multiresistant Klebsiella pneumoniae in a neonatal nursery: the importance of maintenance of infection control policies and procedures in the prevention of outbreaks. J Hosp Infect 1992; 22:197-205.
7. Royle J, Halasz S, Eagles G, et al. Outbreak of extended spectrum beta lactamase producing Klebsiella pneumoniae in a neonatal unit. Arch Dis Child Fetal Neonatal Ed 1999; 80:F64-8. (Pubitemid 29129602)
8. Macrae MB, Shannon KP, Rayner DM, Kaiser AM, Hoffman PN, French GL. A simultaneous outbreak on a neonatal unit of two strains of multiply antibiotic resistant Klebsiella pneumoniae controllable only by ward closure. J Hosp Infect 2001; 49:183-192
9. Pessoa-Silva CL, Meurer Moreira B, Camara Almeida V, et al. Extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a neonatal care intensive care unit: risk factors for infection and colonization. J Hosp Infect 2003; 53:198-206. (Pubitemid 38002055)
10. Ben-Hamouda T, Foulon T, Ben-Mahrenz K. Involvement of SHV-12 and SHV-2a encoding plasmids in outbreaks of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a Tunisia neonatal ward. Microb Drug Resist 2004;10:132-138 (Pubitemid 38879013)
11. Rice LB, Carias LL, Bonomo RA, Shlaes DM. Molecular genetics of resistance to both ceftazidime and beta-lactam beta-lactamase inhibitor combination in Klebsiella pneumoniae and in vivo response to beta-lactam therapy. J Infect Dis 1996; 173:151-158 (Pubitemid 126664476)
12. Thauvin-Eliopoulos C, Tripodi MF, Moellering RC Jr, Eliopoulos GM. Efficacies of pipperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 1997; 41:1053-1057 (Pubitemid 27194184)
13. Kim YK, Pai H, Lee HJ, et al. Bloodstream infections by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 2002; 46:1481-1491 (Pubitemid 34415332)
14. Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39:2206-2212 (Pubitemid 32531482)
15. Wong-Beringer A, Hindler J, Loeloff M, et al. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin Infect Dis 2002; 34:135-146 (Pubitemid 34028343)
16. Tumbarello M, Spanu T, Sanguinetti M, et al. Bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 2006; 50:498-504. (Pubitemid 43190958)
17. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended-spectrum-beta- lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2006; 50:1257-1262
18. Henshke-Bar-Meir R, Yinnon AM, Rudensky B, Attias D, Schlesinger Y, Raveh D. Assessment of the clinical significance of production of extended-spectrum-beta-lactamases (ESBL) by Enterobacteriaceae. Infection 2006; 34:66-74. (Pubitemid 43747436)
19. Melzer M, Peterson I. Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Infect 2007; 55:254-259 (Pubitemid 47244918)
20. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended spectrum b-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 60:913-920 (Pubitemid 47617735)
21. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993; 119:353-358 (Pubitemid 23310083)
22. Naumovski L, Quinn JP, Miyashiro D, et al. Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients. Antimicrob Agents Chemother 1992; 36:1991-1996
23. Schiappa DA, Hayden MK, Matushek MG, et al. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. J Infect Dis 1996; 174:529-536 (Pubitemid 26299686)
24. Paterson DL, Hujer KM, Hujer AM, et al. International Klebsiella study group. Extended-spectrum beta-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type beta-lactamases. Antimicrob Agents Chemother 2003; 47:3554-3560
25. Woodford N, Tierno PM Jr, Young K, et al. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center. Antimicrob Agents Chemother 2004; 48:4793-4799 (Pubitemid 39577686)
26. Corbella X, Montero A, Pujol M, et al. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multi-resistant Acinetobacter baumannii. J Clin Microbiol 2000; 38:4086-4095 (Pubitemid 32233209)
27. Troillet N, Samore MH, Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis 1997; 25:1094-1098 (Pubitemid 27513193)
28. DiNubile MJ, Chow JW, Satishchandran V, et al. Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapem versus piperacillin-tazobactam therapy for intraabdominal infections. Antimicrob Agents Chemother 2005; 49:3217-3221 (Pubitemid 41060564)
29. Kim SY, Park YJ, Yu JK, et al. Prevalence and mechanisms of decreased susceptibility to carbapenems in Klebsiella pneumoniae isolates. Diagn Microbiol Infect Dis 2007; 57:85-91. (Pubitemid 44908824)
30. National Committee for Clinical Laboratory Standards (NCCLS). Performance Standards for Antimicrobial Susceptibility Testing, 11th Informational Supplement, M100-S11. Wayne, PA: National Committee for Clinical Laboratory Standards, 2001.
31. Sehgal R, Gaind R, Chellani H, Agarwal P. Extended-spectrum beta lactamase-producing gram-negative bacteria: clinical profile and outcome in a neonatal intensive care unit. Ann Trop Paediatr 2007; 27:45-54. (Pubitemid 47628961)
32. Romero L, Lopez L, Rodriguez-Bario J, Hernandez Ramon J, Martinez-Martinez L, Pascual A. Long-term study of the frequency of Escherichia coli and Klebsiella pneumoniae isolates producing extended-spectrum β-lactamases. Clin Microbiol Infect 2005; 11:625-631 (Pubitemid 41051378)
33. Kang CI, Kim SH, Park WB, et al. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004; 48:4574-4581 (Pubitemid 39577656)
34. Marra AR, Wey SB, Castelo A, et al. Nosocomial bloodstream infections caused by Klebsiella pneumoniae: impact of extended-spectrum β-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence. BMC Infect Dis 2006; 6:24. (Pubitemid 43299046)
35. Chiu S, Huang YC, Lien RI, Chou YH, Lin TY. Clinical features of nosocomial infections by extended-spectrum beta-lactamase-producing Enterobacteriaceae in neonatal intensive care units. Acta Paediatr 2005; 94:1644-1649 (Pubitemid 41754321)
36. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infections. J Intern Med 1998; 244:379-386 (Pubitemid 28513125)
37. Byl B, Clevenbergh P, Jacobs F, et al. Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia. Clin Infect Dis 1999; 29:60-68 (Pubitemid 29336802)
38. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patients' outcome in the ICU setting. Chest 2000; 118:9-11. (Pubitemid 30485502)
39. Hyle EP, Lipworth AD, Zaoutis TE, Nachamkin I, Bilker WB, Lautenbach E. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: variability by site of infection. Arch Intern Med 2005; 165:1375-1380 (Pubitemid 40973420)
40. Paterson DL, Ko WC, Von Gotteberg A, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004; 39:31-37
41. Tumbarello M, Sanguinetti M, Montuori E, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-blactamase- producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007; 51:1987-1994 (Pubitemid 46903084)
42. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32:1162-1171 (Pubitemid 32390110)
43. Kang CI, Kim SH, Kim DM, et al. Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beat-lactamase-producing Klebsiella pneumoniae. Infect Control Hosp Eidemiol 2004; 25:860-867 (Pubitemid 40036764)
44. Pillay T, Pillay DG, Adhikari M, Sturm AW. Piperacillin/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates. Am J Perinatol 1998; 15:47-51. (Pubitemid 28072978)